ReviewTissue engineering. Part B, Reviews2016
Emerging In Vitro Liver Technologies for Drug Metabolism and Inter-Organ Interactions.
Review in Tissue engineering. Part B, Reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Applicability of next-generation risk assessment generic PBK models and their performance within the chemical domain.Archives of toxicology · 2026Article
- Bioprinting of hepatic tissue model using photocrosslinkable dECM-containing composite hydrogel.Materials today. Bio · 2025Article
- Emerging biotechnologies for engineering liver organoids.Bioactive materials · 2025Review
- Review
- Gut-liver microphysiological systems revealed potential crosstalk mechanism modulating drug metabolism.PNAS nexus · 2024Article
- Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics.Open biology · 2022Review
- Recapitulation of First Pass Metabolism Using 3D Printed Microfluidic Chip and Organoid.Cells · 2021Article
- Preservation of heparin-binding EGF-like growth factor activity on heparin-modified poly(RSC advances · 2021Article
- Characterization of Huh7 cells after the induction of insulin resistance and post-treatment with metformin.Cytotechnology · 2020Article
- Art of Making Artificial Liver: Depicting Human Liver Biology and Diseases in Mice.Seminars in liver disease · 2020Review
- Liver Bioreactor Design Issues of Fluid Flow and Zonation, Fibrosis, and Mechanics: A Computational Perspective.Journal of functional biomaterials · 2020Review
- A 3D Cell Culture Organ-on-a-Chip Platform With a Breathable Hemoglobin Analogue Augments and Extends Primary Human Hepatocyte FunctionsFrontiers in molecular biosciences · 2020Article
- Rapid maturation of the hepatic cell line Huh7 via CDK inhibition for PXR dependent CYP450 metabolism and induction.Scientific reports · 2019Article
- A simplified 3D liver microsphere tissue culture model for hepatic cell signaling and drug-induced hepatotoxicity studies.International journal of molecular medicine · 2019Article
- Exposure time versus cytotoxicity for anticancer agents.Cancer chemotherapy and pharmacology · 2019Article
- Microfluidic Multitissue Platform for Advanced Embryotoxicity Testing In Vitro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme.Theranostics · 2019Article
- Generation of functional human hepatocytes in vitro: current status and future prospects.Inflammation and regeneration · 2019Review
- Prediction of metabolism-induced hepatotoxicity on three-dimensional hepatic cell culture and enzyme microarrays.Archives of toxicology · 2018Article
- Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools.Current drug metabolism · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro liver models provide essential information for evaluating drug metabolism, metabolite formation, and hepatotoxicity. Interfacing liver models with other organ models could provide insights into the desirable as well as unintended systemic side effects of therapeutic agents and their metabolites. Such information is invaluable for drug screening processes particularly in the context of secondary organ toxicity. While interfacing of liver models with other organ models has been achieved, platforms that effectively provide human-relevant precise information are needed. In this concise review, we discuss the current state-of-the-art of liver-based multiorgan cell culture platforms primarily from a drug and metabolite perspective, and highlight the importance of media-to-cell ratio in interfacing liver models with other organ models. In addition, we briefly discuss issues related to development of optimal liver models that include recent advances in hepatic cell lines, stem cells, and challenges associated with primary hepatocyte-based liver models. Liver-based multiorgan models that achieve physiologically relevant coupling of different organ models can have a broad impact in evaluating drug efficacy and toxicity, as well as mechanistic investigation of human-relevant disease conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.